• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Gold nanoparticles hold promise for pancreatic cancer treatment

October 21, 2016 By Sarah Faulkner

Gold nanoparticles hold promise for pancreatic cancer treatmentGold nanoparticles could be an important part of developing a treatment for pancreatic cancer, according to new research published yesterday in the journal ACS Nano. 

Previous work demonstrated that gold nanoparticles can be an effective vehicle to carry chemotherapy drugs into tumors. They can also act as a target to enhance the impact of radiation on tumors. Lead researcher Priyabrata Mukherjee has shown that the nanoparticles can limit tumor growth and curb metastasis in a model of ovarian cancer in mice.

New research by Mukherjee’s team shows that the nanoparticles can effectively disrupt tumor formation in mouse models of pancreatic cancer. The work highlighted details about cellular communication around pancreatic tumors. Gold nanoparticles interrupt this communication and reduce the cellular growth and migration that normally occurs near the tumors.

The microenvironment around a tumor comes from “bidirectional crosstalk” between pancreatic cancer cells and pancreatic stellate cells. The researchers observed that gold nanoparticles can impair protein secretion in both cell types, reducing activation of pancreatic stellate cells.

The size of the gold nanoparticles used in this study were not toxic to healthy cells.

The National Cancer Institute estimates that 53,000 new cases of pancreatic cancer will be diagnosed in the US this year and over 40,000 of those patients will die.

Filed Under: Drug-Device Combinations, Featured, Nanoparticles, Oncology, Research & Development

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS